There will invariably be short term selling pressure . Instos that hold both GMM and GXY will have to reweight post merger . Good time to top up if you're in it for the long haul .
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%